Skip to content

Operating Income at other companies

Cytokinetics logo
CytokineticsCYTK
-$183.62M-18.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$73.23M+15.6%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$125.28M-2.4%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$164.13M-196%
Scholar Rock logo
Scholar RockSRRK
-$102.02M-32.3%

Segments

By segment

See full
Single Reportable-$54.12M-17.7%

Other financials

Income statement

See full
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s operating income?
Edgewise Therapeutics, Inc. (EWTX) reported operating income of -$54.12M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s operating income changed year-over-year?
Edgewise Therapeutics, Inc.'s operating income decreased by 17.7% year-over-year, from -$45.96M to -$54.12M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s operating income?
Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s operating income has grown at a 45.1% compound annual growth rate (CAGR), from -$43.22M to -$191.41M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.